Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Hepat Res Treat. 2010;2010:901216. doi: 10.1155/2010/901216. Epub 2010 Sep 21.

Can engineered "designer" T cells outsmart chronic hepatitis B?

Author information

  • 1Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, 81675 München, Germany.


More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered "designer" T cells.

Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk